Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132706 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HDAC3HDAC8LSSMAPT | |
| SCHEMBL6134902 | 0.95 | ALDH1A1 (0.50) | ALDH1A1LSSMAPTPDE6DACACB | |
| SCHEMBL6134832 | 0.92 | HDAC3 (0.49) | ALDH1A1HDAC3HDAC8MAPTPDE6D | |
| SCHEMBL6133632 | 0.91 | HDAC3 (0.48) | ALDH1A1HDAC3HDAC8MAPTTSHR | |
| SCHEMBL6132214 | 0.90 | MEN1 (0.43) | ALDH1A1HDAC3HDAC8MAPTTSHR | |
| SCHEMBL6135350 | 0.88 | HDAC3 (0.47) | ALDH1A1HDAC3HDAC8MAPTPDE6D | |
| SCHEMBL6134735 | 0.87 | SMYD3 (0.43) | ALDH1A1HDAC3HDAC8LSSMAPT | |
| SCHEMBL6132370 | 0.87 | SMYD3 (0.43) | ALDH1A1HDAC3HDAC8LSSMAPT | |
| SCHEMBL6132500 | 0.87 | SMYD3 (0.43) | ALDH1A1HDAC3HDAC8LSSMAPT | |
| SCHEMBL6132756 | 0.86 | ALDH1A1 (0.45) | ALDH1A1HDAC3HDAC8MAPTPDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | ALDH1A1 4718/4885HDAC3 1534/4885HDAC8 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.